--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-24-098457" form_type: "8-K" ticker: null cik: "0001733413" company_name: "TFF Pharmaceuticals, Inc." filed_at: "2024-11-14T23:59:59+00:00" generated_at: "2026-05-30T00:31:39.000110+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # TFF Pharmaceuticals dissolves, terminates all employees, appoints new CEO to wind down ## Summary - Board approved Plan of Dissolution subject to stockholder vote; license pact with UT Austin terminated. - Substantially all employees terminated Nov 15; estimated $1.8M in severance and exit costs. - Entire board and top officers (CEO, CFO, CMO) resigned; Craig Jalbert appointed sole director/officer. - Jalbert to receive $10K/month until shareholder vote, then $50K/year for three years post-dissolution. - Company will wind down operations and dissolve, pending stockholder approval of the plan. ## SEC filing metadata - accession: 0001213900-24-098457 - form_type: 8-K - cik: 0001733413 - company_name: TFF Pharmaceuticals, Inc. - filed_at: 2024-11-14T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.02, 2.05, 5.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/ea0221102-8k_tffpharma.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-24-098457 - JSON: https://secwatch.observer/filing/0001213900-24-098457.json - Plain text: https://secwatch.observer/filing/0001213900-24-098457.txt ## Key facts - Executive change Kirk Coleman departed as Chief Financial Officer at TFF Pharmaceuticals, Inc.. - Action: ceased serving - Role: Chief Financial Officer source text: Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Zamaneh Mikhak departed as Chief Medical Officer at TFF Pharmaceuticals, Inc.. - Action: ceased serving - Role: Chief Medical Officer source text: Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Harlan Weisman departed as President/Chief Executive Officer at TFF Pharmaceuticals, Inc.. - Action: ceased serving - Role: President/Chief Executive Officer source text: Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Brandi Roberts resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Craig R. Jalbert was appointed as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary at TFF Pharmaceuticals, Inc.. - Action: appointed - Role: President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary source text: the Board appointed Craig R. Jalbert, age 63, as the Company's President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole member of the Board, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Thomas King resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Harlan Weisman resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Stephen Rocamboli resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Craig R. Jalbert was appointed as Sole member of the Board at TFF Pharmaceuticals, Inc.. - Action: appointed - Role: Sole member of the Board source text: the Board appointed Craig R. Jalbert, age 63, as the Company's President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and sole member of the Board, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Catherine Lee resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Executive change Robert J. Mills resigned as Member of the Board at TFF Pharmaceuticals, Inc.. - Action: resigned - Role: Member of the Board source text: Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024. evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm - Restructurings & Charges TFF Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.8 million (substantially all of its employees). - Type: restructuring - Charge: approximately $1.8 million - Headcount: substantially all of its employees source text: On November 14, 2024, in connection with the planned wind down of the Company’s operations, the Board of the Company unanimously approved a reduction-in-force (the “Reduction in Force”) of substantially all of its employees to be effective on November 15, 2024. The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $1.8 million evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024098457/0001213900-24-098457-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.